

**DAFTAR PUSTAKA**

- Abdullah, L. N. & Chow, E. K.-H. 2013. Mechanisms of chemoresistance in cancer stem cells. *Clinical and translational medicine*, 2, 1-9.
- Akinbami,A et al. Full blood count pattern of pre chemotherapy breast cancer patients in Lagos, Nigeria.2013. *Caspian Journal Intern Medicine*
- American Cancer Society. Breast Cancer Prevention and Early Detection. 2015. Available at <http://www.cancer.org/acs/groups/cid/documents/webcontent/003165-pdf.pdf>. Cited on Jan 12<sup>th</sup>, 2019
- Ardiansyah AO. *Surgical Mapping Oncology Series :Breast Cancer*. 2015. Surabaya: Airlangga University Press. Pp 7-25.
- Artacho,A et al. Tumor microenvironment and breast cancer progression a complex scenario.2012. *Cancer Biology and Therapy* 13:1
- Audrina GW, Purhadi, Purwanto H. Faktor-Faktor yang Mempengaruhi Tingkat Keberhasilan Kemoterapi Pada Pasien Penderita Kanker Payudara di RSUD Dr. Soetomo Dengan Menggunakan Regresi Logistik Ordinal. *Jurnal Sains dan Seni Pomits* 2014. 3(1): 2337-52.
- BaeJ,M and Kim E,H. Breast density and risk of breast cancer in asian women: a meta analysis of observational studies.2016. *Journal of Prventive Medicine and Public Health*
- Baruch, B. Host microenvironment in breast cancer developmnet, Inflammatory cells,cytokines and chemokines in breast cancer progression: reciprocal tumor microenviroment interactions.2002.*Breast Cancer Research Vol 5 No 1*
- BIESAGA, B., NIEMIEC, J., ZIOBRO, M., WYSOCKA, J. & KRUCZAK, A. 2011. Prognostic potential of topoisomerase II $\alpha$  and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy. *The Breast*, 20, 338-350.
- Breast Cancer Agency. Epirubicin. Feb 2017. Available at: <http://www.bccancer.bc.ca/drug-database site/.pdf>. Cited on Jan 20<sup>th</sup>, 2019.
- Caliskan,B and Korkmaz,A.N. Can neutrophil/lymphocyte ratio be a predictor for bone metastases of solid tumors. *World journal of nuclear medicine*
- Cardoso F, COsta A, Senkus E et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Annals of Oncology* 2017; 28: 16–33.

- Chen,W.Y.2015. Factor That Modify Breast Cancer Risk In Women. Uptodate. Wolters Kluwer
- Connolly, R. M. & Stearns, V. 2013. Current approaches for neoadjuvant chemotherapy in breast cancer. *European journal of pharmacology*, 717, 58-66.
- DENKERT, C., SINN, B. V., ISSA, Y., MÜLLER, B. M., MAISCH, A., UNTCH, M., VON MINCKWITZ, G. & LOIBL, S. 2011. Prediction of response to neoadjuvant chemotherapy: new biomarker approaches and concepts. *Breast Care*, 6, 265-272.
- Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur Jour Cancer* 2009; 45:228-47.
- Ellisen LW, Isakoff SJ. Incorporating Translational Research in the Treatment of Locally Advanced Breast Cancer. In: Taghian et al. *Breast Cancer: A Multidisciplinary Approach to Diagnosis and Treatment*. 2010. USA: Demos Medical Publishing. pp 195-8.
- Elyasinia,F et al. Neutrophil lymphocyte ratio in different stages of breast cancer.2016. *Acta Medica Iran* 2017;55(4)
- Foukakis, T and Bergh, J. 2015. Prognostic and Predictive Factors in Early, non Metastatic Breast Cancer. Uptodate. Wolters Kluwer.
- Franceschini G, Terribile D, Magno S et al. Update in the treatment of locally advanced breast cancer: a multidisciplinary approach. *Eur Rev Med Prahmacol Sci* 2007; 11: 283-9.
- Fumagalli, D., Andre, F., Piccart-Gebhart, MJ., Sotiriou, C & Desmedt, C., 2012, *Moleccular Biology in Breast Cancer: Should Moleccular Classifiers be Assessed by Conventional tools or by Gene Expression Arrays?*, Elseviers, 84, 58-69.
- Furuya,Y.2019. Early Neutropenia on day Treated with Adjuvant Docetaxel based Chemotherapy in Early Breast Cancer Patients: Putative Mechanism within the Neutrophil Pool System.Plos One
- Graziano, et al.2019. Combination of peripheral neutrophil to lymphocyte ratio and platelet to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. *The Breast* Vol 44 April 2019
- GUDKOV, A. V., ZELNICK, C. R., KAZAROV, A. R., THIMMAPAYA, R., SUTTLE, D. P., BECK, W. T. & RONINSON, I. B. 1993. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. *Proceedings of the National Academy of Sciences*, 90, 3231-3235.

- Ji, H., et al. 2016. The Prognostic and Predictive Value of The Lymphocyte to Monocyte ratio in Luminal-type Breast Cancer Patients treated with CEF Chemotherapy. *Oncotarget*, Vol 7, No23
- Jia, W et al. The peripheral blood neutrophil to lymphocyte ratio is superior to the lymphocyte to monocyte ratio for predicting the long term survival of triple negative breast cancer patients. 2015. *plos one*
- Kumar, R. Et al. The neutrophil lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. 2015. *British Journal of cancer*.
- Lee, A., Lim, W., Moon, B.-I., Paik, N.-S., Koh, S.-H. & Song, J.-Y. 2011. Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline-and taxane-based chemotherapy. *Journal of breast cancer*, 14, 283-288.
- Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. *Nature Reviews Cancer* 2003; 3: 330-8.
- Luo, G et al. Blood neutrophil lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. 2015. *Annual Surgical Oncology*.
- Manuaba TW. Kanker Payudara dalam: *Panduan Penatalaksanaan kanker solid PERABOI*. 2010. Jakarta: CV Sagung Seto. pp 17-45.
- Mao, Y et al. Stroma Cells in Tumor Microenvironment and Breast Cancer. 2013. *Cancer Metastatic Rev June* ;32(0):303-315
- Mendoza, M.G. et al. Neutrophils drive accelerated tumor progression in the collagen dense mammary tumor microenvironment. 2016. *Breast cancer research*.
- Noh, H et al. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease specific survival in breast cancer patients. 2013. *Journal of breast cancer* March 16(1)
- Ochonma et al. Efficacy of neoadjuvant chemotherapy in down staging locally advanced pre-menopausal breast cancer in Eastern Nigeria: Is four courses adequate?. 2014. *Journal of Cancer Research and Therapeutics*.
- Opal L Reddy and Sophia K Apple, Breast Cancer Biomarker Changes after Neoadjuvant Chemotherapy: A Single Institution Experience and Literature Review. *Clinics in Oncology Review Article* Published: 23 Mar, 2017
- Orditura, M et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis free survival (DMFS) in early breast cancer: a propensity score matched analysis. *ESMO Open* 2016

- Oyan, B. et al. The prognostic factors for local disease free survival and distant disease free survival in stage I-III breast cancer patients treated with adjuvant CAF chemotherapy. 2002. THOD Turk Hematologi Onkoloji Dergisi.
- Papademetriou K, Ardavanis A, Kountourakis P. Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium. *J Thorac Dis* 2010; 2: 160-170.
- PharmKGB. Cyclophosphamide pathway, pharmacodynamics. 2010. Available at: <https://www.pharmgkb.org/pathway/PA2035>. Cited on Jan 20<sup>th</sup>, 2019
- PharmKGB. Doxorubicin Pathway (Cancer Cell), Pharmacodynamics. 2010. Available at: <https://www.pharmgkb.org/pathway/PA165292163>. Cited on Jan 20<sup>th</sup>, 2019
- Place et al. The microenvironment in breast cancer progression biology and implications for treatment. 2011. Breast cancer research
- Powell, D. et al. Chemokine signaling and the regulation of bidirectional leukocyte migration in interstitial tissues. 2017. *Cell rep* May 23;19(8)
- Prasetyo, et al. 2015. Angka Banding Neutrofil/Limfosit di Karsinoma Payudara. Indonesian Journal of Clinical Pathology and Medical Laboratory. Vol 21 No 2
- Press, M. F., Sauter, G., Buse, M., Bernstein, L., Guzman, R., Santiago, A., Villabos, I. E., Eierman W., Pienkowski, T. & Martin, M. 2011. Alteration of topoisomerase II- $\alpha$  gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. *Journal of Clinical Oncology*, 29, 859-867.
- Purwanto, H., Handojo, D., Haryono, SJ & Harahap WA., Panduan Penatalaksanaan Kanker Payudara. PERABOI, Jakarta, 2015.
- Pusat Data dan Informasi Kementerian Kesehatan Indonesia. Situasi Kanker di Indonesia. Oktober 2016. Available at <http://www.depkes.go.id/resources/download/pusdatin/infodatin/InfoDatin%20Bulan%20Peduli%20Kanker%20Payudara%202016.pdf>. Cited on Jan 10<sup>th</sup>, 2019
- Querol, E.U et al. Neutrophils in cancer: two sides of the same coin. 2015. *Journal of Immunology Research*. Hindawi Publishing Corporation Vol 2015
- Sethi et al., Histopathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer. *Indian J Cancer*. 2013 Jan-Mar;50(1):58-64.
- Silva, F.M et al. Development and maturation of neutrophils. 1994. *Veterinary Quarterly* 16:4

- SPARANO, J. A., GOLDSTEIN, L. J., CHILDS, B. H., SHAK, S., BRASSARD, D., BADVE, S., BAEHNER, F. L., BUGARINI, R., ROWLEY, S. & PEREZ, E. 2009. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. *Clinical Cancer Research*, 15, 7693-7700
- Templeton, A.J. et al. Prognostic role of neutrophil to lymphocyte ratio in solid tumors: a systematic review and meta analysis. 2013. *Journal National Cancer Institution* 106 (6)
- Thompson AM, Moulder- Thompson SL. Neoadjuvant treatment of breast cancer. *Ann Oncol.* 2012;23:x231-236.
- WHO. Breast Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. 2012. available at <http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp>. Cited on Jan 10<sup>th</sup>, 2019
- Wilson, T., Longley, D. & Johnston, P. 2006. Chemoresistance in solid tumours. *Annals of oncology*, 17, x315-x324.
- Xuan, Li et al. 2018. The Value of Neutrophil to Lymphocyte Ratio For Response and Prognostic Effect of Neoadjuvant Chemotherapy in Solid Tumors: A Systematic Review and Meta-Analysis. *Journal of Cancer*, Ivyspring International Publisher.
- Zhu, Y et al. Platelet lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. 2017. *Oncotarget* vol 8 (No 1)